Nebenwirkungen · Levetiracetam Actavis Group
Levetiracetam Actavis Group 100 mg/ml oral solution · Abschnitt 4.8 · PDF-Seite 10
HOS-125201 · Präparat HOS-096021
Adverse reactions reported in clinical studies (adults, adolescents, children and infants> 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1000 to <1/100); rare (≥ 1/10000 to <1/1000) and very rare (<1/10000).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-26T13:19:00Z · SHA-256 922445385f872a12bb2cbb8705a2e36092efd96aae1726df5bc6e965246270d2 · Passage 57860358ba3b576d3528e833498b376b9e4f3160d65503cd899b17b8d11fc672 · Zeichen 737–1195 im Abschnitt